Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
AVEO Pharmaceuticals, Inc is a biotechnology business based in the US. AVEO Pharmaceuticals shares (AVEO) are listed on the NASDAQ and all prices are listed in US Dollars. AVEO Pharmaceuticals employs 19 staff and has a trailing 12-month revenue of around USD$5.9 million.
|52-week range||USD$2.2301 - USD$10.71|
|50-day moving average||USD$8.2067|
|200-day moving average||USD$6.2047|
|Wall St. target price||USD$12|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.028|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing AVEO Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AVEO Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AVEO Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 85x. In other words, AVEO Pharmaceuticals shares trade at around 85x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Revenue TTM||USD$5.9 million|
|Gross profit TTM||USD$10.8 million|
|Return on assets TTM||-30.89%|
|Return on equity TTM||-96.78%|
|Market capitalisation||USD$249.2 million|
TTM: trailing 12 months
There are currently 739,525 AVEO Pharmaceuticals shares held short by investors – that's known as AVEO Pharmaceuticals's "short interest". This figure is 21.5% up from 608,492 last month.
There are a few different ways that this level of interest in shorting AVEO Pharmaceuticals shares can be evaluated.
AVEO Pharmaceuticals's "short interest ratio" (SIR) is the quantity of AVEO Pharmaceuticals shares currently shorted divided by the average quantity of AVEO Pharmaceuticals shares traded daily (recently around 462203.125). AVEO Pharmaceuticals's SIR currently stands at 1.6. In other words for every 100,000 AVEO Pharmaceuticals shares traded daily on the market, roughly 1600 shares are currently held short.
However AVEO Pharmaceuticals's short interest can also be evaluated against the total number of AVEO Pharmaceuticals shares, or, against the total number of tradable AVEO Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AVEO Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 AVEO Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0282% of the tradable shares (for every 100,000 tradable AVEO Pharmaceuticals shares, roughly 28 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AVEO Pharmaceuticals.
Find out more about how you can short AVEO Pharmaceuticals stock.
We're not expecting AVEO Pharmaceuticals to pay a dividend over the next 12 months.
AVEO Pharmaceuticals's shares were split on a 1:10 basis on 20 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AVEO Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for AVEO Pharmaceuticals shares which in turn could have impacted AVEO Pharmaceuticals's share price.
Over the last 12 months, AVEO Pharmaceuticals's shares have ranged in value from as little as $2.2301 up to $10.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVEO Pharmaceuticals's is 1.2375. This would suggest that AVEO Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, acute myeloid leukemia, and pancreatic cancer; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. AVEO Pharmaceuticals, Inc. has collaboration and license agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Kirin Co., Ltd. It has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.